Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.

The Journal of pathology - 1 Dec 2013

Tsang Yvonne T, Deavers Michael T, Sun Charlotte C, Kwan Suet-Yan, Kuo Eric, Malpica Anais, Mok Samuel C, Gershenson David M, Wong Kwong-Kwok

Abstract excerpt

BRAF and KRAS mutations in ovarian serous borderline tumours (OSBTs) and ovarian low-grade serous carcinomas (LGSCs) have been previously described. However, whether those OSBTs would progress to LGSCs or whether those LGSCs were developed from OSBT precursors in previous studies is unknown. Therefore, we assessed KRAS and BRAF mutations in tumour samples from 23 recurrent LGSC patients with a known initial...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzimidazoles
Share to Cell Death

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cystadenocarcinoma, Serous

Share to Kaplan-Meier Estimate

Share to MAP Kinase Kinase Kinases

Share to Neoplasm Grading

Share to Neoplasm Recurrence, Local

Share to ras Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 24549645
DOI: 10.1002/path.4252
PMCID: PMC4095747

Genes

KRAS
BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.PMID 24549645Read ↗

The molecular pathology of ovarian serous borderline tumors.Semantic proximity Read ↗

Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas.Semantic proximity Read ↗

Spectrum of BRAF Mutations and Gene Rearrangements in Ovarian Serous Carcinoma.Semantic proximity Read ↗

KRAS mutation in primary ovarian serous borderline tumors correlates with tumor recurrence.Semantic proximity Read ↗

Low‐grade serous carcinomas of the ovary contain very few point mutationsSemantic proximity Read ↗

Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes.Semantic proximity Read ↗

Somatic genetic alterations in synchronous and metachronous low‐grade serous tumours and high‐grade carcinomas of the adnexaSemantic proximity Read ↗

Mutational spectrum in clinically aggressive low-grade serous carcinoma/serous borderline tumors of the ovary-Clinical significance of BRCA2 gene variants in genomically stable tumors.Semantic proximity Read ↗

Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors.Semantic proximity Read ↗

Molecular characteristics of low-grade serous carcinoma in effusions.Semantic proximity Read ↗

Somatic Genomic and Transcriptomic Characterization of Primary Ovarian Serous Borderline Tumors and Low-Grade Serous Carcinomas.Semantic proximity Read ↗

BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.